KADCYLA 160 mg, powder for concentrate for infusion bottle, 20 ml
Active ingredients: Ado-trastuzumab emtansine
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Powder for concentrate for infusionbottle, 20 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KADCYLA 160 mg, poudre pour solution à diluer pour perfusion
- Pharmaceutical form
- poudre pour solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 20 ml
- Marketing authorisation holder
- ROCHE REGISTRATION (ALLEMAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 10 Nov 2014
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64565603CIP75857610CIP133400958576102Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TRASTUZUMAB EMTANSINEpoudre | 160 mg · un flacon de poudre pour solution à diluer | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.